T. Rowe Price Associates’s scPharmaceuticals SCPH Stock Holding History

T. Rowe Price Associates’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,431	Closed	-$111K	–	3129
2025 Q3	$111K	Hold	19,431	–	–	﹤0.01%	2902
2025 Q2	$75K	Buy	19,431 +4,288	+28%	+$13.3K	﹤0.01%	2950
2025 Q1	$40K	Hold	15,143	–	–	﹤0.01%	2956
2024 Q4	$54K	Buy	+15,143	New	+$58K	﹤0.01%	2932
2018 Q2	–	Sell	-305,850	Closed	-$3.79M	–	2598
2018 Q1	$3.79M	Buy	305,850 +1,141	+0.4%	+$15.3K	﹤0.01%	1462
2017 Q4	$3.68M	Buy	+304,709	New	+$4.3M	﹤0.01%	1463

T. Rowe Price Associates's SCPH Position: Q4 2025 in Review

T. Rowe Price Associates sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 19,431 shares — an estimated $111K sold.

T. Rowe Price Associates first reported a position in SCPH in Q4 2017 and held it in 6 quarters. The position peaked at $3.79M in Q1 2018. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

T. Rowe Price Associates reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
T. Rowe Price Associates sold 19,431 scPharmaceuticals shares in Q4 2025, an estimated $111K.
T. Rowe Price Associates first reported a position in scPharmaceuticals in Q4 2017 and held it in 6 quarters.
T. Rowe Price Associates's scPharmaceuticals position peaked at $3.79M in Q1 2018.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.